http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-109928956-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D401-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-506 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate | 2019-02-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2020-10-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2020-10-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-109928956-B |
| titleOfInvention | Compound for targeted ubiquitination degradation of EGFR protein, and pharmaceutical composition and application thereof |
| abstract | The invention discloses a compound with a structure shown in the following formula and capable of targeted ubiquitination degradation of EGFR protein or a pharmaceutically acceptable salt thereof, and also discloses a pharmaceutical composition comprising the compound or the pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier and a preparation prepared from the pharmaceutical compound. The compounds show excellent EGFR degradation effect and have good anti-tumor activity, so the invention also discloses the application of the compounds in preparing EGFR protein inhibitors and preparing drugs for preventing or/and treating cancers, and the compounds have great application prospects in the field of medical treatment. |
| priorityDate | 2019-02-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 67.